No Data
No Data
No Data
No Data
No Data
HC Wainwright & Co. : Reviva Pharmaceuticals (RVPH.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
HC Wainwright & Co. : Reviva Pharmaceuticals (RVPH.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
Zhitong FinanceApr 22 18:20
Analysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)
TipRanksApr 22 18:20
HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals with a Buy and maintains $20 price target.
Analyst UpgradesApr 22 18:15
AbbVie Buyout Cerevel Posts Late-stage Win for Parkinson's Disease Drug
Seeking AlphaApr 18 19:00
Benchmark: Revised Reviva Pharmaceuticals (RVPH.US) rating and adjusted from Speculative Buy to Specified Buy, target price $17.00.
Benchmark: Revised Reviva Pharmaceuticals (RVPH.US) rating and adjusted from Speculative Buy to Specified Buy, target price $17.00.
Zhitong FinanceApr 16 22:00
Benchmark Reiterates Speculative Buy on Reviva Pharmaceuticals, Maintains $17 Price Target
Benchmark analyst Bruce Jackson reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Speculative Buy and maintains $17 price target.
BenzingaApr 16 21:59
No Data
No Data